跳至主要内容
临床试验/NCT00085332
NCT00085332已完成2 期

A Phase II Evaluation of Weekly Docetaxel (NSC #628503) in the Treatment of Recurrent or Persistent Endometrial Carcinoma

Gynecologic Oncology Group149 个研究点 分布在 1 个国家开始时间: 2004年7月最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
已完成
试验地点
149

研究概览

简要总结

RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: This phase II trial is studying how well docetaxel works in treating patients with recurrent or persistent endometrial carcinoma (cancer).

详细描述

OBJECTIVES:

  • Determine the antitumor activity of docetaxel in patients with recurrent or persistent endometrial carcinoma.
  • Determine the toxicity of this drug in these patients.

OUTLINE: This is a multicenter study.

Patients receive docetaxel IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Patients are followed every 3 months for 2 years and then every 6 months for 3 years.

研究设计

研究类型
Interventional
主要目的
Treatment
盲法
None

入排标准

性别
Female
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究者

申办方类型
Network
责任方
Sponsor

研究点 (149)

Loading locations...

相似试验